South Korea: Time to apply for PTA

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

South Korea: Time to apply for PTA

Sponsored by

hanolip-400px.png
the-eleventh-hour-5017535-1920.jpg

Three years ago, Korea adopted a new patent term adjustment (PTA) system. As many readers know, PTA is a system that allows extension of a patent term to the patent owner to compensate for an unreasonable delay during the prosecution phase.

The duration of a patent term is of interest to every patent owner. However, in some industries (such as pharmaceuticals), it is not just a matter of interest, because it may be the most important aspect of the patent. Maximising the protection period is a key factor in patent portfolio management for drug developers. For that reason, it is worth knowing how the Korean system is structured, how it is different from other jurisdictions and how to get an advantage from this complicated system.

So why is it important to think about the PTA, now, in 2016? The answer is, because the present time is the earliest period when a patent owner can enjoy the benefit from the new PTA system. Even though the PTA was adopted in 2012, patents can actually enjoy this benefit starting from March 15 2016 because a request for PTA can be made for patents which were issued later than: (a) four years after the filing date or (b) three years after the date of requesting examination, whichever is later.

The extendable period to a normal patent term, which is 20 years from the filing date, is calculated by the following simple equation (see also the figure):

Extendable Time = [from reference date to Issue date] – [delay attributable to the applicant].

table

The reference date is a later date of (a) or (b) above.

Regarding the delay, the Enforcement Decree of the Korean Patent Act lists more than 40 such situations where the period of delay may be deducted from the extendable time period.

One important point of emphasis about the Korean PTA system is that the patentee must file a separate request to KIPO because it is not automatically awarded to the patentee. KIPO does not calculate the extendable term or notify the patentee of its eligibility. Further, the request must be made within three months from the date of paying the issue fee. The procedure thereafter is similar to the procedure of a regular patent application. After examining the PTA application, KIPO will issue an office action if it determines that the application does not meet the statutory requirements.

Another thing to keep in mind is the period it takes to respond to the office action. It is important to note that this responding time period may be deducted from the extendable time period if an amendment was filed. This is the case even if the applicant timely filed a response to the office action. However, if the patent was granted, without an amendment, based only on the written statement or written argument, this responding time period will not be deducted from the extendable time period. This feature is somewhat unique in the Korean system.

In addition to the PTA, Korea has another way of extending the patent protection – patent term extension (PTE). PTE allows drug developers to extend the duration of the patent term by up to five years, whereas PTA applies to patents in all technical fields. Therefore, with the PTA in conjunction with the PTE, patent owners can now enjoy a more comprehensive protection of their patent rights in Korea than ever before.

Min Son

Partner, Hanol IP & Law

E: minson@hanollawip.com


HANOL Intellectual Property & Law

6th Floor, 163, Yang Jae Cheon-Ro, Gang Nam-Gu

Seoul 06302, Republic of Korea

Tel: +82 2 942 1100

Fax: +82 2 942 2600

hanol@hanollawip.com

www.hanollawip.com



more from across site and SHARED ros bottom lb

More from across our site

A $110 million US verdict against Apple and an appellate order staying a $39 million trademark infringement finding against Amazon were also among the top talking points
Attorneys are watching how AI affects trademark registrations and whether a SCOTUS ruling from last year will have broader free speech implications
Patent lawyers explain why they will be keeping an eye on the implications of a pharma case and on changes at the USPTO in the second half of 2025
The insensitive reaction to a UK politician crying on TV proves we have a long way to go before we can say we are tackling workplace wellbeing
Adrian Percer says he was impressed by the firm’s work on billion-dollar cases as well as its culture
In our latest interview with women IP leaders, Catherine Bonner at Murgitroyd discusses technology, training, and teaching
Developments included an update in the VAR dispute between Ballinno and UEFA, the latest CMS updates, and a swathe of market moves
The LMG Life Sciences Americas Awards is thrilled to present the 2025 shortlist
A new order has brought the total security awarded to a Canadian tech company to $45 million, the highest-ever by an Indian court in an IP case
Andrew Blattman reflects on how IP practices have changed and shares his hopes for increased AI use and better performance on the stock market
Gift this article